文献速递冠心病血脂与心血管预防

他汀不耐受与心肌梗死后冠脉事件及全因死亡风险

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该研究纳入105,329例2007至2013年因心肌梗死住院后起始中高强度他汀治疗的Medicare受益人,比较他汀不耐受者与高依从者的结局。中位随访1.9至2.3年间,他汀不耐受与复发心肌梗死和冠心病事件风险升高相关,但与全因死亡率无显著关联。

要点

  • 他汀不耐受者复发心肌梗死风险较高依从者升高(HR 1.50,95%CI 1.30-1.73)。
  • 他汀不耐受者冠心病事件风险较高依从者升高(HR 1.51,95%CI 1.34-1.70)。
  • 他汀不耐受与全因死亡率无显著关联(HR 0.96,95%CI 0.87-1.06)。

核心结论

  • 他汀不耐受与复发心肌梗死和冠心病事件风险增加相关,但与全因死亡率无关。

研究设计与样本

  • 研究纳入105,329例2007至2013年因心肌梗死住院后起始中强度或高强度他汀剂量的Medicare受益人。
  • 他汀不耐受定义为下调他汀剂量并起始依折麦布、从他汀换为依折麦布单药、有横纹肌溶解或抗高脂血症不良事件诊断代码后下调或停用他汀,或起始后1年内换用≥3种他汀。
  • 高他汀依从性定义为出院后一年内覆盖天数比例≥80%。

主要发现

  • 总体1,741例(1.65%)存在他汀不耐受,55,567例(52.8%)高依从。
  • 中位随访1.9至2.3年间,发生4,450例复发心肌梗死、6,250例冠心病事件和14,311例死亡。
  • 他汀不耐受者复发心肌梗死发生率为41.1/1000人年,高依从者为30.1/1000人年。
  • 他汀不耐受者冠心病事件发生率为62.5/1000人年,高依从者为43.8/1000人年。
  • 他汀不耐受者全因死亡率发生率为79.9/1000人年,高依从者为94.2/1000人年。

关键数值与推荐

  • 多变量校正后,他汀不耐受 vs 高依从的复发心肌梗死HR为1.50(95%CI 1.30-1.73)。
  • 多变量校正后,他汀不耐受 vs 高依从的冠心病事件HR为1.51(95%CI 1.34-1.70)。
  • 多变量校正后,他汀不耐受 vs 高依从的全因死亡率HR为0.96(95%CI 0.87-1.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients report adverse reactions to, and may not tolerate, statin therapy. These patients may be at increased risk for coronary heart disease (CHD) events and mortality. OBJECTIVES: This study evaluated the risk for recurrent myocardial infarction (MI), CHD events, and all-cause mortality in Medicare beneficiaries with statin intolerance and in those with high adherence to statin therapy. METHODS: We studied 105,329 Medicare beneficiaries who began a moderate- or high-intensity statin dosage after hospitalization for MI between 2007 and 2013. Statin intolerance was defined as down-titrating statins and initiating ezetimibe therapy, switching from statins to ezetimibe monotherapy, having International Classification of Diseases, 9th revision, diagnostic codes for rhabdomyolysis or an antihyperlipidemic adverse event, followed by statin down-titration or discontinuation, or switching between ≥3 types of statins within 1 year after initiation. High statin adherence over the year following hospital discharge was defined as proportion of days covered ≥80%. Recurrent MI, CHD events (recurrent MI or a coronary revascularization procedure), and mortality were identified from 1 year after hospital discharge through December 2014. RESULTS: Overall, 1,741 patients (1.65%) had statin intolerance, and 55,567 patients (52.8%) had high statin adherence. Over a median of 1.9 to 2.3 years of follow-up, there were 4,450 recurrent MIs, 6,250 CHD events, and 14,311 deaths. Compared to beneficiaries with high statin adherence, statin intolerance was associated with a 36% higher rate of recurrent MI (41.1 vs. 30.1 per 1,000 person-years, respectively), a 43% higher rate of CHD events (62.5 vs. 43.8 per 1,000 person-years, respectively), and a 15% lower rate of all-cause mortality (79.9 vs. 94.2 per 1,000 person-years, respectively). The multivariate-adjusted hazard ratios (HR) comparing beneficiaries with statin intolerance versus those with high statin adherence were 1.50 (95% confidence interval [CI]: 1.30 to 1.73) for recurrent MI, 1.51 (95% CI: 1.34 to 1.70) for CHD events, and 0.96 (95% CI: 0.87 to 1.06) for all-cause mortality. CONCLUSIONS: Statin intolerance was associated with an increased risk for recurrent MI and CHD events but not all-cause mortality.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017. PMID: 28302290. doi:10.1016/j.jacc.2016.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。